Grifols is engaged in developing, manufacturing and distributing a range of plasma derivative products. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend the lives of individuals who suffer from chronic and acute conditions. Co. also specializes in providing infusion solutions, nutrition products, medical devices, diagnostic instrumentation and reagents for use in hospitals and clinics. Co.'s products and services are used by healthcare providers in approximately 100 countries. Co.'s business is organized into three divisions: Bioscience, Diagnostic, Hospital and Raw Materials.
  • TickerGRF
  • ISINES0171996087
  • ExchangeMadrid Stock Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountrySpain
Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - GRIFOLS : Année difficile mais des fondamentaux solides - ACHAT, OC 38€ (vs 41€)

Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - Etude sectorielle Medtech : Détecter les faux positifs

GRIFOLS SA reduced its risk exposure resulting in an upgrade to Slightly Positive

GRIFOLS SA (ES), a company active in the Biotechnology industry, reduced its market risk and raised its general evaluation. The independent financial analyst theScreener awarded an improved star rating to the company, which now shows 2 out of 4 possible stars; its market behaviour has improved and can be considered as defensive. theScreener believes that this new assessment merits an overall rating upgrade to Slightly Positive. As of the analysis date March 13, 2020, the closing price was EUR 26.01 and its potential was estimated at EUR 35.15.

Feasibility Study Results in December to be a Catalyst for this Junior

Feasibility Study Results in December to be a Catalyst for this Junior

Maxime Kogge

Grifols : Quality comes at a (high) price. We are buyers of the new 2025 issue at 1.5% or higher and of the new 2027 at 2% or higher

Grifols has launched the refinancing of its secured bank facilities with a new debt offering of $ 6.5bn (€ 5.6bn). The new facilities include for the first time € 1.14bn of senior secured bonds due 2025 and 2027. The existing € 1bn senior unsecured bond due 2025 is unaffected. - We continue to favour the group's business model as heavy investments efforts are currently dilutive on margins and cash flow but strengthen the business profile and contribute to margin stability in the l...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Another test of support Heightened trade tensions have caused global equities to move from resistance to support in a matter of days. Additional consolidation - i.e., no breakdowns - on the broad global indexes (MSCI ACWI, ACWI ex-US, EAFE, and EM) remains the most likely scenario. At the same time, new cracks are beginning to show and as a result we believe global equities are vulnerable to a breakdown. • New cracks emerging. Breakdowns in crude oil and new lows for the STOXX 600 Bank supersector are two recent developments which have dampened our overall outlook... see charts below. • Tes...


Short term view - GRIFOLS SA : Prices are making further progress.

The trend is bullish. Prices are making further progress. The targets are at €27.09 and then €28.10. The break of €21.60 would endanger the trend.


Analyse court terme - GRIFOLS SA : La progression des cours se poursuit.

La tendance est haussière. La progression des cours se poursuit. Les objectifs sont à 27,09 € puis 28,10 €. La rupture de 21,60 € mettrait la tendance en danger.